Cargando…

Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

BACKGROUND/AIMS: We investigated the efficacy and toxicity of a weekly schedule of docetaxel and cisplatin as a first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). METHODS: In this study, 18 patients with previously diagnosed R/M HNSCC wer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Moon Jin, Kim, Sung Min, Jung, Hyun Ae, Hong, Jung Yong, Chang, Won Jin, Choi, Moon Ki, Kim, Hye Sook, Sun, Jong-Mu, Park, Keunchil, Ahn, Myung-Ju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718762/ https://www.ncbi.nlm.nih.gov/pubmed/29914230 http://dx.doi.org/10.3904/kjim.2017.234

Ejemplares similares

Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck
por: Trieu, Vanessa, et al.
Publicado: (2018)

A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer
por: Kim, Hye Ryeon, et al.
Publicado: (2022)

Multicenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck
por: Bae, Woo Kyun, et al.
Publicado: (2013)

Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Kim, Hana, et al.
Publicado: (2023)

Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea
por: Kim, Hyera, et al.
Publicado: (2020)

A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine
por: Lee, Keun-Wook, et al.
Publicado: (2017)

Concurrent Chemoradiation with Low-Dose Weekly Cisplatin in Locally Advanced Stage IV Head and Neck Squamous Cell Carcinoma
por: Kang, Myoung Hee, et al.
Publicado: (2015)

Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas
por: William, William N., et al.
Publicado: (2018)

The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis
por: Kim, Ryul, et al.
Publicado: (2016)

Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma
por: Ock, Chan-Young, et al.
Publicado: (2017)

Docetaxel in the treatment of squamous cell carcinoma of the head and neck
por: Rapidis, Alexander, et al.
Publicado: (2008)

Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: A multicenter retrospective analysis
por: Lee, So Yeon, et al.
Publicado: (2018)

A Phase II Study of Genexol‐PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Keam, Bhumsuk, et al.
Publicado: (2019)

Response Rate of Cisplatin Plus Docetaxel as Primary Treatment in Locally Advanced Head and Neck Carcinoma (Squamous Cell Types)
por: Nouman, Maryum, et al.
Publicado: (2020)

Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma
por: Fayette, Jérôme, et al.
Publicado: (2015)

Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck
por: Huang, Kie Kyon, et al.
Publicado: (2016)

Metabolic parameters on baseline (18)F-FDG PET/CT are potential predictive biomarkers for immunotherapy in patients with head and neck squamous cell carcinoma
por: Kwon, Hye Ryeong, et al.
Publicado: (2022)

The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma
por: Ku, Bo Mi, et al.
Publicado: (2016)

Concurrent Chemoradiotherapy With Weekly Low-Dose Cisplatin for Japanese Patients With Head and Neck Squamous Cell Carcinoma
por: Shinohara, Shogo, et al.
Publicado: (2021)

3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck – a multicentre, retrospective analysis
por: Helfenstein, Seth, et al.
Publicado: (2019)

A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck
por: Couteau, C, et al.
Publicado: (1999)

Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck
por: Posner, M R, et al.
Publicado: (2003)

Alteration status and prognostic value of MET in head and neck squamous cell carcinoma
por: Cho, Yoon Ah, et al.
Publicado: (2016)

First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study
por: Falco, Agustín, et al.
Publicado: (2022)

Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma
por: Lim, Sun Min, et al.
Publicado: (2019)

Aripiprazole sensitizes head and neck cancer cells to ionizing radiation by enhancing the production of reactive oxygen species
por: Jeong, Hyeon‐Jeong, et al.
Publicado: (2022)

Effect of definitive hypo-fractionated radiotherapy concurrent with weekly cisplatin in locally advanced squamous cell carcinoma of the head and neck
por: Abdelhafiz, Nora, et al.
Publicado: (2023)

Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)
por: Katori, H, et al.
Publicado: (2004)

Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors
por: Kim, Hongsik, et al.
Publicado: (2021)

Granulocytic Sarcoma in the Head and Neck: CT and MR Imaging Findings
por: Noh, Bong Wan, et al.
Publicado: (2009)

Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer
por: Fuchs, Hannah, et al.
Publicado: (2018)

Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer
por: Roh, Jong-Lyel, et al.
Publicado: (2014)

The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
por: Jung, Hyun Ae, et al.
Publicado: (2020)

The comparison of acute toxicity in 2 treatment courses: Three-weekly and weekly cisplatin treatment administered with radiotherapy in patients with head and neck squamous cell carcinoma
por: Mackiewicz, Jacek, et al.
Publicado: (2017)

Change of the Expression of Human Telomerase Reverse Transcriptase mRNA and Human Telomerase RNA after Cisplatin and 5-Fluorouracil Exposure in Head and Neck Squamous Cell Carcinoma Cell Lines
por: Lee, Byung-Joo, et al.
Publicado: (2007)

Concurrent Weekly Cisplatin and Simultaneous Integrated Boost-IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma—An Institutional Experience
por: Ahmed, Imtiaz, et al.
Publicado: (2022)

Decitabine Rescues Cisplatin Resistance in Head and Neck Squamous Cell Carcinoma
por: Viet, Chi T., et al.
Publicado: (2014)

Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer
por: Lee, S-H, et al.
Publicado: (2004)

Inhibitor of DNA binding 2 is a novel therapeutic target for stemness of head and neck squamous cell carcinoma
por: Bae, Woo Jin, et al.
Publicado: (2017)

Feasibility of Induction Docetaxel, Cisplatin, 5-Fluorouracil, Cetuximab (TPF-C) Followed by Concurrent Cetuximab Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Charalambakis, Nikolaos, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_v14q4cdv9ujrqiu65m14nm5i21